Stem cell-based bioregenerative therapy of osteoporosis: literature review

Cell and Organ Transplantology. 2023; 11(1):4-13.
DOI: 10.22494/cot.v11i1.146

Stem cell-based bioregenerative therapy of osteoporosis: literature review

Nishkumay O.^1,2, Mike K. S. Chan², Nalapko Y.², Grygorieva N.³, Nikitin O.¹, KordubailoI.¹, Rudenko Iu.¹

¹Bogomolets National Medical University, Kyiv, Ukraine
²European Wellness Academy, Edenkoben, Germany
³D. F. Chebotarev State Institute of Gerontology, the National Academy of Medical Sciences of Ukraine, Ukrainian Center of Osteoporosis, Kyiv, Ukraine

Abstract

Aging is an inevitable process of our civilization. Since ancient times, scientists have tried to solve the mystery of aging. The research continues to this day. The most common diseases of old age are disorders of the musculoskeletal system. Among them, osteoporosis continues to occupy the third place in the structure of overall morbidity and mortality. Such statistical data make us think about the search for a possible cause of the disease at the molecular level.
The purpose of this study was to analyze the literature data on modern directions of osteoporosis treatment, including stem-cells based bioregenerative medicine. An analytical review of literature data was conducted using the information analysis of Medline (PubMed), Web of Science and Scopus databases, Google Scholar and the Cochrane Central Register of Controlled Trials (CENTRAL) from 2018 to 2022 using the keywords “osteoporosis”, bioregenerative therapy”, “stem cell therapy”.
Recent results of preclinical experimental studies have shown the effectiveness of the introduction of new bioregenerative technologies. In particular, the use of mesenchymal stem cells, exosomes and miRNAs. Preclinical studies on MSC transplantation in the treatment of osteoporosis indicate an increase in osteogenic differentiation, an increase in BMD. Exosomes also may play multiple roles in the treatment of osteoporosis: improving the disbalance between osteoclasts and osteoblasts, structural modification of exosomes and transmitters’ drug function. The promotion of bone regeneration of exosomes has been shown in animal models. Exosomes with active ingredients can treat a variety of skeletal disorders including osteoporosis and osteoporotic fractures.
The results of recent research of the bone disorder treatment based on stem cells therapy have shown convincing prospects for new approaches.

Key words: osteoporosis; stem cell-based therapy; exosomes; regeneration

Full Text PDF

References

1. Shyamala V, Harini R, Manikandan D, Riyaz SM. Acute Respiratory Distress Syndrome (ARDS). In: An Epidemiological Update on COVID-19. 2022;1. https://doi.org/10.2174/9789815050325122010005

2. Huppert LA, Matthay MA, Ware LB. Pathogenesis of acute respiratory distress syndrome. Semin Respir Crit Care Med. 2019;40(1):31-39. Available from: https://doi.org/10.1055/s-0039-1683996 https://doi.org/10.1055/s-0039-1683996 PMid:31060086 PMCid:PMC7060969

3. Michael AM, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019; 5:18. Available from: https://doi.org/10.1038/s41572-019-0069-0 https://doi.org/10.1038/s41572-019-0069-0 PMid:30872586 PMCid:PMC6709677

4. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017; 377:562-72. Available from: https://doi.org/10.1056/NEJMra1608077 https://doi.org/10.1056/NEJMra1608077 PMid:28792873

5. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. Jama. 2016; 315(8): 788-800. Available from: https://doi.org/10.1001/jama.2016.0291 https://doi.org/10.1001/jama.2016.0291 PMid:26903337

6. Herrero R, Sánchez G, Asensio I, López E, et al. Liver-lung interactions in acute respiratory distress syndrome. Intensive Care Med Exp. 2020;8(1):1-13. Available from: https://doi.org/10.1186/s40635-020-00337-9 https://doi.org/10.1186/s40635-020-00337-9 PMid:33336286 PMCid:PMC7746785

7. Kallet RH, Lipnick MS, Zhuo H, Pangilinan LP, Gomez A. Characteristics of nonpulmonary organ dysfunction at onset of ARDS based on the Berlin definition. 2019. Available from: https://doi.org/10.4187/respcare.06165 https://doi.org/10.4187/respcare.06165 PMid:30992403

8. Dawood, R. M., Salum, G. M., & Abd El-Meguid, M. The impact of COVID-19 on liver injury. The American Journal of the Medical Sciences, 2022, 363.2: 94-103. Available from: https://doi.org/10.1016/j.amjms.2021.11.001 https://doi.org/10.1016/j.amjms.2021.11.001 PMid:34752738 PMCid:PMC8571104

9. Harnisch, L. O., Baumann, S., Mihaylov, D., Kiehntopf, M., Bauer, M., Moerer, O., & Quintel, M. Biomarkers of cholestasis and liver injury in the early phase of acute respiratory distress syndrome and their pathophysiological value. Diagnostics, 2021;11(12): 2356. Available from: https://doi.org/10.3390/diagnostics11122356 https://doi.org/10.3390/diagnostics11122356 PMid:34943592 PMCid:PMC8699895

10. Guillot A, Tacke F. Liver macrophages: old dogmas and new insights. Hepatology communications. 2019; 3(6):730-743. Available from: https://doi.org/10.1002/hep4.1356 https://doi.org/10.1002/hep4.1356 PMid:31168508 PMCid:PMC6545867

11. Weber M, Lambeck S, Ding N, Henken S, Kohl M, Deigner HP, et al. Hepatic induction of cholesterol biosynthesis reflects a remote adaptive response to pneumococcal pneumonia. The FASEB Journal. 2012; 26(6):2424-2436. Available from: https://doi.org/10.1096/fj.11-191957 https://doi.org/10.1096/fj.11-191957 PMid:22415311

12. Quinton LJ, Blahna MT, Jones MR, Allen E, Ferrari JD, Hilliard KL, et al. Hepatocyte-specific mutation of both NF-κB RelA and STAT3 abrogates the acute phase response in mice. J Clin Investig. 2012: 122(5):1758-1763. Available from: https://doi.org/10.1172/JCI59408 https://doi.org/10.1172/JCI59408 PMid:22466650 PMCid:PMC3336975

13. Dickson RP. The lung microbiome and ARDS. It is time to broaden the model. 2018. Available from: https://doi.org/10.1164/rccm.201710-2096ED https://doi.org/10.1164/rccm.201710-2096ED PMid:29091746 PMCid:PMC6005245

14. Dickson RP, Singer BH, Newstead MW, Falkowski NR, Erb-Downward JR, Standiford TJ, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol. 2016; 1(10):1-9. Available from: https://doi.org/10.1038/nmicrobiol.2016.113 https://doi.org/10.1038/nmicrobiol.2016.113 PMid:27670109 PMCid:PMC5076472

15. de Jong PR, González-Navajas JM, Jansen NJG. The digestive tract as the origin of systemic inflammation. Crit Care. 2016; 20(1):1-12. Available from: https://doi.org/10.1186/s13054-016-1458-3 https://doi.org/10.1186/s13054-016-1458-3 PMid:27751165 PMCid:PMC5067918

16. Massey VL, Poole LG, Siow DL, Torres E, Warner NL, Schmidt RH, et al. Chronic Alcohol Exposure Enhances Lipopolysaccharide‐Induced Lung Injury in Mice: Potential Role of Systemic Tumor Necrosis Factor-Alpha. Alcohol Clin Exp Res. 2015; 39(10):1978-1988. Available from: https://doi.org/10.1111/acer.12855 https://doi.org/10.1111/acer.12855 PMid:26380957 PMCid:PMC4804458

17. Massey VL. Potential role of the gut/liver/lung axis in alcohol-induced tissue pathology. Biomolecule. 2015; 5(4):2477-2503. Available from: https://doi.org/10.3390/biom504247718. https://doi.org/10.3390/biom5042477 PMid:26437442 PMCid:PMC4693244

18. Domscheit H, Hegeman MA, Carvalho N, Spieth PM. Molecular dynamics of lipopolysaccharide-induced lung injury in rodents. Front Physiol. 2020;11:36. Available from: https://doi.org/10.3389/fphys.2020.00036 https://doi.org/10.3389/fphys.2020.00036 PMid:32116752 PMCid:PMC7012903

19. George T, Chakraborty M, Giembycz MA, Newton R. A bronchoprotective role for Rgs2 in a murine model of lipopolysaccharide-induced airways inflammation. Allergy Asthma Clin Immunol. 2018;14(1):1-14. Available from: https://doi.org/10.1186/s13223-018-0266-5 https://doi.org/10.1186/s13223-018-0266-5 PMid:30305828 PMCid:PMC6166284

20. de Souza Xavier Costa N, Ribeiro Júnior G, dos Santos Alemany AA, Belotti L, Zati DH, Frota Cavalcante M, et al. Early and late pulmonary effects of nebulized LPS in mice: An acute lung injury model. PLoS One. 2017;12(9):e0185474. Available from: https://doi.org/10.1371/journal.pone.0185474 https://doi.org/10.1371/journal.pone.0185474 PMid:28953963 PMCid:PMC5617199

21. Barnett-Vanes A, Sharrock A, Birrell MA, Rankin S. A single 9-colour flow cytometric method to characterise major leukocyte populations in the rat: validation in a model of LPS-induced pulmonary inflammation. PLoS One. 2016;11(1):e0142520. Available from: https://doi.org/10.1371/journal.pone.0142520 https://doi.org/10.1371/journal.pone.0142520 PMid:26764486 PMCid:PMC4713146

22. Roos AB, Berg T, Ahlgren KM, Grunewald J, Nord M. A method for generating pulmonary neutrophilia using aerosolized lipopolysaccharide. J Vis Exp. 2014;(94):e51470. Available from: https://doi.org/10.3791/51470 https://doi.org/10.3791/51470 PMid:25548888 PMCid:PMC4396917

23. Fan X, Li L, Ye Z, Zhou Y, Tan WS, Yang J. Advances in umbilical cord mesenchymal stem cells: A review of their potential in regenerative medicine. Expert Opin Biol Ther. 2021;21(10):1355-1366. Available from: https://doi.org/10.1080/14712598.2021.1921837

24. Redko O, Dovgalyuk A, Dovbush A, Nebesna Z, Yakubyshyna L, Krynytska I. Liver injury associated with acute respiratory distress syndrome and the prospects of mesenchymal stem cells therapy for liver failure. Cell Organ Transpl. 2021;9(2):136-142. Available from: https://doi.org/10.22494/cot.v9i2.13025 https://doi.org/10.22494/cot.v9i2.130

25. Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells Int. 2018;2018:3057624. Available from: https://doi.org/10.1155/2018/3057624 https://doi.org/10.1155/2018/3057624 PMid:30013600 PMCid:PMC6022321

26. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252-260. Available from: https://doi.org/10.1038/nbt.2816 https://doi.org/10.1038/nbt.2816 PMid:24561556 PMCid:PMC4320647

27. Fröhlich E. Acute Respiratory Distress Syndrome: Focus on Viral Origin and Role of Pulmonary Lymphatics. Biomedicines. 2021 Nov;9(11):1732. Available from: https://doi.org/10.3390/biomedicines9111732 https://doi.org/10.3390/biomedicines9111732 PMid:34829961 PMCid:PMC8615541

28. Krynytska I, Marushchak M, Birchenko I, Dovgalyuk A, Tokarskyy O. COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review). Iran J Microbiol. 2021;13(6):728-738. Available from: https://doi.org/10.18502/ijm.v13i6.8072. https://doi.org/10.18502/ijm.v13i6.8072 PMid:35222850 PMCid:PMC8816697

29. Strassmair M. Alpha-1-Antitrypsin expressing Mesenchymal Stem Cells (MSC-AAT) for the treatment of severe cases of COVID-19 infection. 2020. https://doi.org/10.31219/osf.io/yv8g3 PMid:34629682 PMCid:PMC7577864

30. Iglesias M, Butrón P, Torre-Villalvazo I, Torre-Anaya EA, Sierra-Madero J, Rodriguez-Andoney JJ, Nario-Chaidez HF. Mesenchymal stem cells for the compassionate treatment of severe acute respiratory distress syndrome due to COVID-19. Aging and disease. 2021;12(2):360. Available from: https://doi.org/10.14336/AD.2020.1218 https://doi.org/10.14336/AD.2020.1218 PMid:33815870 PMCid:PMC7990366

31. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Zhao RC. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and disease. 2020;11(2):216. Available from: https://doi.org/10.14336/AD.2020.0228 https://doi.org/10.14336/AD.2020.0228 PMid:32257537 PMCid:PMC7069465

32. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, .Matthay MA. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. The Lancet Respiratory Medicine. 2015;3(1):24-32. Available from: https://doi.org/10.1016/S2213-2600(14)70291-7 https://doi.org/10.1016/S2213-2600(14)70291-7 PMid:25529339

33. Sanchez-Diaz M, Quiñones-Vico MI, Sanabria de la Torre R, Montero-Vílchez T, Sierra-Sánchez A, Molina-Leyva A, Arias-Santiago S. Biodistribution of mesenchymal stromal cells after administration in animal models and humans: a systematic review. J Clin Med. 2021;10(13):2925. Available from: https://doi.org/10.3390/jcm10132925 https://doi.org/10.3390/jcm10132925 PMid:34210026 PMCid:PMC8268414

34. Livingstone, S. A., Wildi, K. S., Dalton, H. J., Usman, A., Ki, K. K., Passmore, M. R., & Fraser, J. F. Coagulation Dysfunction in Acute Respiratory Distress Syndrome and Its Potential Impact in Inflammatory Subphenotypes. Frontiers in Medicine, 2021:8: 723217. Available from: https://doi.org/10.3389/fmed.2021.723217 https://doi.org/10.3389/fmed.2021.723217 PMid:34490308 PMCid:PMC8417599

35. Gando, S., Fujishima, S., Saitoh, D., Shiraishi, A., Yamakawa, K., Kushimoto, S., & Umemura, Y. The significance of disseminated intravascular coagulation on multiple organ dysfunction during the early stage of acute respiratory distress syndrome. Thrombosis research, 2020;191: 15-21. Available from: https://doi.org/10.1016/j.thromres.2020.03.023 https://doi.org/10.1016/j.thromres.2020.03.023 PMid:32353745

36. Chang, J. C. Acute respiratory distress syndrome as an organ phenotype of vascular microthrombotic disease: based on hemostatic theory and endothelial molecular pathogenesis. Clinical and Applied Thrombosis/Hemostasis, 2019;25: 1076029619887437. Available from: https://doi.org/10.1177/1076029619887437 https://doi.org/10.1177/1076029619887437 PMid:31775524 PMCid:PMC7019416

37. Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121:27-42. Available from: https://doi.org/10.1016/j.addr.2017.05.007 https://doi.org/10.1016/j.addr.2017.05.007 PMid:28506744 PMCid:PMC5682243

38. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14:181-194. Available from: https://doi.org/10.1038/nri3623 https://doi.org/10.1038/nri3623 PMid:24566915

39. Schon HT, Weiskirchen R. Immunomodulatory effects of transforming growth factor-β in the liver. Hepatobiliary Surg Nutr. 2014 Dec;3(6):386-406. Available from: https://doi.org/10.3978/j.issn.2304-3881.2014.11.06

40. Dooley S, Ten Dijke P. TGF-β in progression of liver disease. Cell and tissue research. 2012 Jan;347(1):245-256. Available from: https://doi.org/10.1007/s00441-011-1246-y https://doi.org/10.1007/s00441-011-1246-y PMid:22006249 PMCid:PMC3250614

41. 41. Yang N, Ma W, Ke Y, Liu H, Chu J, Sun L, Zhang C, Lin R. Transplantation of adipose-derived stem cells ameliorates Echinococcus multilocularis-induced liver fibrosis in mice. PLOS Neglected Tropical Diseases. 2022 Jan;16(1):e0010175. Available from: https://doi.org/10.1371/journal.pntd.0010175 https://doi.org/10.1371/journal.pntd.0010175 PMid:35100287 PMCid:PMC8830670

42. Fathy M, Okabe M, Saad Eldien HM, Yoshida T. AT-MSCs antifibrotic activity is improved by eugenol through modulation of TGF-β/Smad signaling pathway in rats. Molecules. 2020 Jan;25(2):348. Available from: https://doi.org/10.3390/molecules25020348 https://doi.org/10.3390/molecules25020348 PMid:31952158 PMCid:PMC7024200

43. Liu Q, Lv C, Jiang Y, Luo K, Gao Y, Liu J, et al. From hair to liver: Emerging application of hair follicle mesenchymal stem cell transplantation reverses liver cirrhosis by blocking the TGF-β/Smad signaling pathway to inhibit pathological HSC activation. PeerJ. 2022;10:e12872. Available from: https://doi.org/10.7717/peerj.12872 https://doi.org/10.7717/peerj.12872 PMid:35186473 PMCid:PMC8855721

44. Liu Q, Lv C, Huang Q, et al. ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF-β/Smad signaling pathway. Cell Death Discovery. 2022;8(1):51. Available from: https://doi.org/10.1038/s41420-022-00846-4 https://doi.org/10.1038/s41420-022-00846-4 PMid:35136027 PMCid:PMC8827057

45. Jang YO, Kim SH, Cho MY, Kim KS, Park KS, Cha SK, Park HJ, Yu E, Lee YB, Kim MY, Baik SK. Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis. Biochemical and biophysical research communications. 2018 Jan 1;497(1):264-71. Available from: https://doi.org/10.1016/j.bbrc.2017.12.091 https://doi.org/10.1016/j.bbrc.2017.12.091 PMid:29269297

46. McGill MR. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J. 2016;15:817. Available from: https://doi.org/10.17179/excli2016-800

47. Levick C. How to interpret liver function tests. South Sudan Med J. 2017;10(2):40-43.

48. Moriles K, Azer S. Alanine Amino Transferase. StatPearls. 2022.

49. Wang CH, Chen CY, Wang KH, Kao AP, Chen YJ, Lin PH, Chuang KH. Comparing the Therapeutic Mechanism and Immune Response of Human and Mouse Mesenchymal Stem Cells in Immunocompetent Mice With Acute Liver Failure. Stem Cells Transl Med. 2023. Available from: https://doi.org/10.1093/stcltm/szac084 https://doi.org/10.1093/stcltm/szac084 PMid:36610716 PMCid:PMC9887270

50. Hu C, Wu Z, Li L. Pre-treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases. JCMM. 2020; 24(1):40-49. Available from: https://doi.org/10.1111/jcmm.14788 https://doi.org/10.1111/jcmm.14788 PMid:31691463 PMCid:PMC6933358

51. Tsuchiya A, Kojima Y, Ikarashi S, Seino S, Watanabe Y, Kawata Y, et al. Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases. Inflamm Regen. 2017; 37(1): 1-15. Available from: https://doi.org/10.1186/s41232-017-0045-6 https://doi.org/10.1186/s41232-017-0045-6 PMid:29259715 PMCid:PMC5725741

52. Kang H, Kim MY, Eom YW, Baik SK. Mesenchymal stem cells for the treatment of liver disease: present and perspectives. Gut and liver. 2020; 14(3):306. Available from: https://doi.org/10.5009/gnl18412 https://doi.org/10.5009/gnl18412 PMid:31581387 PMCid:PMC7234888

53. 53. Wang YH, Wu DB, Chen B, Chen EQ, Tang H. Progress in mesenchymal stem cell-based therapy for acute liver failure. Stem Cell Res Therapy. 2018; 9(1):1-9. Available from: https://doi.org/10.1186/s13287-018-0972-4 https://doi.org/10.1186/s13287-018-0972-4 PMid:30143052 PMCid:PMC6109312

54. Wang J, Cen P, Chen J, Fan L, Li J, Cao H, et al. Role of mesenchymal stem cells, their derived factors, and extracellular vesicles in liver failure. Stem Cell Res Ther. 2017; 8:137. Available from: https://doi.org/10.1186/s13287-017-0576-4 https://doi.org/10.1186/s13287-017-0576-4 PMid:28583199 PMCid:PMC5460333

55. Gazdic M, Arsenijevic A, Markovic BS, Volarevic A, Dimova I, Djonov V, et al. Mesenchymal stem cell-dependent modulation of liver diseases. Int J Biol Sci. 2017; 13(9):1109. Available from: https://doi.org/10.7150/ijbs.20240 https://doi.org/10.7150/ijbs.20240 PMid:29104502 PMCid:PMC5666326

56. Zhang Y, Li Y, Li W, Cai J, Yue M, Jiang L, et al. Therapeutic effect of human umbilical cord mesenchymal stem cells at various passages on acute liver failure in rats. Stem Cells Int. 2018; 2018. Available from: https://doi.org/10.1155/2018/7159465 https://doi.org/10.1155/2018/7159465 PMid:30538751 PMCid:PMC6261392

57. Huang B, Cheng X, Wang H, et al. Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively. J Transl Med. 2016; 14:45. Available from: https://doi.org/10.1186/s12967-016-0792-1 https://doi.org/10.1186/s12967-016-0792-1 PMid:26861623 PMCid:PMC4746907

58. 58. Cai Y, Zou Z, Liu L, Chen S, Chen Y, Lin Z, Chen Y. Bone marrow-derived mesenchymal stem cells inhibits hepatocyte apoptosis after acute liver injury. Int J Clin Exp. 2015; 8(1): 107-16.

59. Ryu KH, Kim SY, Kim YR, et al. Tonsil-derived mesenchymal stem cells alleviate concanavalin A-induced acute liver injury. Exp Cell Res. 2014; 326:143-154. Available from: https://doi.org/10.1016/j.yexcr.2014.06.007 https://doi.org/10.1016/j.yexcr.2014.06.007 PMid:24954408

60. Ayatollahi M, Hesami Z, Jamshidzadeh A, Gramizadeh B. Antioxidant effects of bone marrow mesenchymal stem cell against carbon tetrachloride-induced oxidative damage in rat livers. Int J Organ Transplant Med. 2014;5(4):166-73.

61. Xu J, Qu J, Cao L, Sai Y, Chen C, He L, … & Wang W. Mesenchymal stem cell-based therapy for acute respiratory distress syndrome: from basic to clinics. Protein & Cell. 2019;10(10):710-727. Available from: https://doi.org/10.1007/s13238-019-0643-3

62. Silva JD, Lopes-Pacheco M, Paz AH, Cruz FF, Melo EB, de Oliveira MV, & Rocco PR. Mesenchymal stem cells from bone marrow, adipose tissue, and lung tissue differentially mitigate lung and distal organ damage in experimental acute respiratory distress syndrome. Critical care medicine. 2018;46(2):e132-e140. Available from: https://doi.org/10.1097/CCM.0000000000002848 https://doi.org/10.1097/CCM.0000000000002848 PMid:29337816

63. Mokhber Dezfouli MR, Jabbari Fakhr M, Sadeghian Chaleshtori S, Dehghan MM, Vajhi A, Mokhtari R. Intrapulmonary autologous transplant of bone marrow-derived mesenchymal stromal cells improves lipopolysaccharide-induced acute respiratory distress syndrome in rabbit. Crit Care. 2018;22:1-13. Available from: https://doi.org/10.1186/s13054-018-2272-x https://doi.org/10.1186/s13054-018-2272-x PMid:30572913 PMCid:PMC6302408

How to cite

Nishkumay O, Mike K S Chan, Nalapko Y, Grygorieva N, Nikitin O, Kordubailo I. Stem cell-based bioregenerative therapy of osteoporosis: literature review. Cell Organ Transpl. 2023; 11(1):4-13. Available from: https://doi.org/10.22494/cot.v11i1.146

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.